Dr Marc Ferrante and colleagues from Belgium reported the outcome of infliximab in ulcerative colitis patients from a single center.
The research team identified predictors of early clinical response.
The research team included 100 ulcerative colitis patients who received infliximab at a single center.
The team reported that 84 patients received 5 mg/kg infliximab.
|65% had an early clinical response|
|Inflammatory Bowel Diseases|
A further 37 patients received a 3-dose infliximab induction at weeks 0, 2, and 6.
The Mayo endoscopic subscore, assessed by sigmoidoscopy before inclusion, was 1, 2, and 3 in 5%, 52%, and 43% of patients, respectively.
The researchers found that 60% had pancolitis, and 63% were on concomitant immunosuppressive therapy.
The team noted that 9% were active smokers, 64% had C-reactive protein 5 mg/dL, and 44% were pANCA positive or ASCA negative.
The research team observed that 5 patients received infliximab because of severe acute colitis refractory to intravenous corticosteroids.
Early complete and partial clinical responses were observed in 41% and 24% of patients.
The team found that patients with early clinical response were significantly younger than nonresponders.
Patients who were pANCA positive or ASCA negative had a significantly lower early clinical response.
The team noted that concomitant immunosuppressive therapy and the use of an infliximab induction scheme did not influence early clinical response.
Only 1 of 5 patients who received infliximab for acute steroid-refractory colitis required colectomy within 2 months.
Dr Ferrante's team concludes, “Infliximab is an efficient therapy in ulcerative colitis, as shown by 65% early clinical response.”
“A pANCA positive or ASCA negative serotype and an older age at first infliximab infusion are associated with a suboptimal early clinical response.”